- Conditions
- Lymphoma
- Interventions
- carmustine, cyclophosphamide, cytarabine, dexamethasone, doxorubicin hydrochloride, methotrexate, vincristine sulfate, low-LET cobalt-60 gamma ray therapy, low-LET photon therapy
- Drug · Radiation
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2006
- U.S. locations
- 21
- States / cities
- Scottsdale, Arizona • Denver, Colorado • Peoria, Illinois + 18 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 121–144
of 413
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Prostate Cancer
- Interventions
- NanoKnife System, Stereotactic Body Radiation Therapy
- Device · Radiation
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Male only
- Enrollment
- 224 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 8
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Ipilimumab, Nivolumab, SBRT
- Drug · Radiation
- Lead sponsor
- Brown University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Endometrial Carcinoma
- Interventions
- Biospecimen Collection, Low-Dose Aspirin, Patient Observation, Questionnaire Administration, Ultrasound Imaging
- Procedure · Drug · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2027 – 2028
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
- Interventions
- Treosulfan
- Drug
- Lead sponsor
- Center for International Blood and Marrow Transplant Research
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 19 more
- Conditions
- Hematologic Malignancies
- Interventions
- CliniMACS® CD34 Reagent System, Fludarabine, Melphalan, anti-thymocyte globulin (rabbit), Rituximab, Total Body Irradiation, Mycophenolate Mofetil, Tacrolimus
- Device · Drug · Radiation
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2026
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • New York, New York
- Conditions
- Cancer, Leukemia, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma
- Interventions
- Fludarabine, Cyclophosphamide, Transplantation
- Drug · Procedure
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 4 Years to 50 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2015
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Breast Neoplasms
- Interventions
- Screening Tomosynthesis, Diagnostic Tomosynthesis
- Device
- Lead sponsor
- American College of Radiology
- Other
- Eligibility
- 25 Years and older · Female only
- Enrollment
- 558 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2013
- U.S. locations
- 2
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Intrahepatic Cholangiocarcinoma
- Interventions
- Gemcitabine, Cisplatin, low dose radiotherapy
- Drug · Radiation
- Lead sponsor
- Allina Health System
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma, Triple Negative Breast Cancer, Non-Small Cell Lung Cancer, Oropharynx Squamous Cell Carcinoma
- Interventions
- vidutolimod, cemiplimab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Duarte, California • La Jolla, California + 17 more
- Conditions
- Sarcoma
- Interventions
- GRID therapy
- Radiation
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Atherosclerotic Cardiovascular Disease
- Interventions
- Coronary Artery Calcium Scan, Carotid Artery Ultrasound, Lipoprotein(a) Measurement, Vascular Function Testing
- Diagnostic Test
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 650 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Leukemia
- Interventions
- therapeutic allogeneic lymphocytes, peripheral blood stem cell transplantation, radiation therapy
- Biological · Procedure · Radiation
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 55 Years to 74 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2001
- U.S. locations
- 2
- States / cities
- Denver, Colorado • Seattle, Washington
- Conditions
- Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, Refractory Anemia With Ringed Sideroblasts, Refractory Cytopenia With Multilineage Dysplasia, Secondary Myelodysplastic Syndromes, Untreated Adult Acute Myeloid Leukemia
- Interventions
- iodine I 131 monoclonal antibody BC8, total-body irradiation, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, fludarabine phosphate, cyclosporine, mycophenolate mofetil, laboratory biomarker analysis
- Radiation · Procedure · Drug + 1 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2010
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Squamous Cell Carcinoma, Head and Neck Cancer, Recurrent Disease
- Interventions
- Erbitux, Taxotere, Low Dose Fractionated Radiation Therapy
- Drug · Radiation
- Lead sponsor
- University of Miami
- Other
- Eligibility
- Not listed
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Splenic Marginal Zone Lymphoma
- Interventions
- Ipilimumab, SD-101, Radiation therapy
- Biological · Drug · Radiation
- Lead sponsor
- Robert Lowsky
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Adult Acute Myeloid Leukemia in Remission, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Myelodysplastic Syndrome, Childhood Renal Cell Carcinoma, Chronic Myelomonocytic Leukemia, Clear Cell Renal Cell Carcinoma, de Novo Myelodysplastic Syndrome, Metastatic Renal Cell Cancer, Previously Treated Myelodysplastic Syndrome, Progression of Multiple Myeloma or Plasma Cell Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult Non-Hodgkin Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Non-Hodgkin Lymphoma, Refractory Anemia, Refractory Anemia With Ringed Sideroblasts, Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Renal Medullary Carcinoma, Type 1 Papillary Renal Cell Carcinoma, Type 2 Papillary Renal Cell Carcinoma, Untreated Adult Acute Lymphoblastic Leukemia, Untreated Adult Acute Myeloid Leukemia, Untreated Childhood Acute Lymphoblastic Leukemia
- Interventions
- Fludarabine Phosphate, Total-Body Irradiation, Peripheral Blood Stem Cell Transplantation, Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Mycophenolate Mofetil
- Drug · Radiation · Procedure
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2004
- U.S. locations
- 8
- States / cities
- Tucson, Arizona • Stanford, California • Atlanta, Georgia + 5 more
- Conditions
- Brain Tumors, Central Nervous System Tumors, Medulloblastoma
- Interventions
- Cisplatin, Cyclophosphamide, Etoposide, Lomustine, Vincristine, Craniospinal Radiation
- Drug · Radiation
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 3 Years to 30 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2011
- U.S. locations
- 3
- States / cities
- Palo Alto, California • Atlanta, Georgia • Philadelphia, Pennsylvania
- Conditions
- Sleep
- Interventions
- Light
- Behavioral
- Lead sponsor
- Palo Alto Veterans Institute for Research
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Breast Cancer
- Interventions
- Accelerated partial breast irradiation
- Device
- Lead sponsor
- Cancer Center of Irvine
- Other
- Eligibility
- 50 Years and older · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 1
- States / cities
- Irvine, California
- Conditions
- High Grade Glioma, MGMT-Unmethylated Glioblastoma, MGMT-Methylated Glioblastoma
- Interventions
- DB107-RRV, DB107-FC, Radiation Therapy (RT), Temozolomide, Magnetic Resonance Imaging (MRI), Surgical resection
- Genetic · Drug · Radiation + 1 more
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2042
- U.S. locations
- 5
- States / cities
- Los Angeles, California • San Diego, California • San Francisco, California + 2 more
- Conditions
- Prostate Cancer
- Interventions
- stereotactic body radiation therapy (SBRT)- 45 Gy, stereotactic body radiation therapy (SBRT) - 47.5 Gy, stereotactic body radiation therapy (SBRT) - 50 Gy (Phase 1), stereotactic body radiation therapy (SBRT) - 50 Gy (Phase 2)
- Radiation
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 120 Years · Male only
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2022
- U.S. locations
- 5
- States / cities
- Aurora, Colorado • Orlando, Florida • Minneapolis, Minnesota + 2 more
- Conditions
- Head and Neck Cancer
- Interventions
- Pembrolizumab, Radiation
- Drug · Radiation
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Chemotherapeutic Agent Toxicity, Cognitive/Functional Effects, Lymphoma, Neurotoxicity, Radiation Toxicity
- Interventions
- Rituximab, Cytarabine, Methotrexate, Procarbazine, Vincristine, low-dose whole-brain radiation therapy
- Biological · Drug · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2022
- U.S. locations
- 44
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 34 more